Brexanolone by Sage Therapeutics for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval

Brexanolone is under clinical development by Sage Therapeutics and currently in Phase I for Post-Traumatic Stress Disorder (PTSD).

Health care policy features prominently in Vance-Walz VP debate

WASHINGTON — The candidates for vice president sparred over the guts of health insurance policy Tuesday during their debate, with Sen. JD Vance (R-Ohio) expanding

October 2, 2024

Shady Medicare Advantage Plan Tactics Blasted at Senate Hearing

A dozen U.S. Senators and three witnesses sharply criticized Medicare Advantage (MA) marketing schemes during a Senate Finance Committee hearing yesterday. Participants blasted the “unscrupulous,”

October 20, 2023

Big Pharma Steps Onto the Psychedelics Wagon | Psychedelic Spotlight

Big Pharma has certainly taken note of the potential therapeutic benefits of psychedelics. Otsuka, a major Japanese Pharmaceutical company, recently signed an agreement to acquire

September 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.